These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3124027)

  • 21. Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients.
    Streifler M; Rabey MJ
    J Neural Transm Suppl; 1983; 19():265-72. PubMed ID: 6421992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial.
    Rascol O; Montastruc JL; Senard JM; Demonet JF; Simonetta M; Rascol A
    Neurology; 1988 Sep; 38(9):1387-91. PubMed ID: 3137488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Tetrud JW; Langston JW
    Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pergolide and selegiline for Parkinson's disease.
    Med Lett Drugs Ther; 1989 Sep; 31(800):81-3. PubMed ID: 2505028
    [No Abstract]   [Full Text] [Related]  

  • 25. A placebo-controlled trial of L-deprenyl in atypical depression.
    McGrath PJ; Stewart JW; Harrison W; Wager S; Nunes EN; Quitkin FM
    Psychopharmacol Bull; 1989; 25(1):63-7. PubMed ID: 2505303
    [No Abstract]   [Full Text] [Related]  

  • 26. The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.
    Elsworth JD; Sandler M; Lees AJ; Ward C; Stern GM
    J Neural Transm; 1982; 54(1-2):105-10. PubMed ID: 6809891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease--an interim analysis.
    Teychenne PF; Parker S
    Acta Neurol Scand Suppl; 1989; 126():119-25. PubMed ID: 2515717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
    Sivertsen B; Dupont E; Mikkelsen B; Mogensen P; Rasmussen C; Boesen F; Heinonen E
    Acta Neurol Scand Suppl; 1989; 126():147-52. PubMed ID: 2515720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's disease.
    Frankel JP; Kempster PA; Stibe CM; Eatough VM; Nathanson M; Lees AJ; Stern GM
    Clin Neuropharmacol; 1989 Oct; 12(5):448-51. PubMed ID: 2514981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease.
    Stern GM; Lees AJ; Hardie R; Sandler M
    Mod Probl Pharmacopsychiatry; 1983; 19():215-9. PubMed ID: 6408407
    [No Abstract]   [Full Text] [Related]  

  • 31. Deprenyl in Parkinson disease.
    Eisler T; Teräväinen H; Nelson R; Krebs H; Weise V; Lake CR; Ebert MH; Whetzel N; Murphy DL; Kopin IJ; Calne DB
    Neurology; 1981 Jan; 31(1):19-23. PubMed ID: 6161320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practical therapeutics: advances in the management of Parkinson's disease.
    Adam AM
    East Afr Med J; 1985 Feb; 62(2):143-6. PubMed ID: 3930202
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
    Csanda E; Tárczy M
    Acta Neurol Scand Suppl; 1983; 95():117-22. PubMed ID: 6428143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy of deprenyl, a specific inhibitor of MAOB.
    Psychopharmacol Bull; 1983; 19(3):328-42. PubMed ID: 6314420
    [No Abstract]   [Full Text] [Related]  

  • 35. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1983; 95():107-11. PubMed ID: 6428141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long term treatment with L-deprenyl.
    Birkmayer W
    J Neural Transm; 1978; 43(3-4):239-44. PubMed ID: 745016
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of L-Deprenyl on on-off phenomena in Parkinson's disease.
    Brodersen P; Philbert A; Gulliksen G; Stigård A
    Acta Neurol Scand; 1985 Jun; 71(6):494-7. PubMed ID: 3927650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease.
    Birkmayer W; Knoll J; Riederer P; Youdim MB
    Mod Probl Pharmacopsychiatry; 1983; 19():170-6. PubMed ID: 6408405
    [No Abstract]   [Full Text] [Related]  

  • 39. Current controversies in the use of selegiline hydrochloride.
    Lees AJ
    J Neural Transm Suppl; 1987; 25():157-62. PubMed ID: 3123602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent observations on the clinical pharmacology of (-)deprenyl.
    Stern GM; Lees AJ; Sandler M
    J Neural Transm; 1978; 43(3-4):245-51. PubMed ID: 745017
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.